NCT06785779 Short-term Treatment Satisfaction in Hidradenitis Suppurativa Patients Initiated on Cosentyx in Routine Clinical Practice in Saudi Arabia
| NCT ID | NCT06785779 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Novartis Pharmaceuticals |
| Condition | Hidradenitis Suppurativa (HS) |
| Study Type | OBSERVATIONAL |
| Enrollment | 77 participants |
| Start Date | 2025-03-10 |
| Primary Completion | 2026-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 77 participants in total. It began in 2025-03-10 with a primary completion date of 2026-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to assess the treatment satisfaction of HS patients newly started on secukinumab in Saudi Arabia, in terms of patient reported convenience, perceived safety, perceived effectiveness and global treatment satisfaction as measured by the treatment satisfaction questionnaire for medication (TSQM) at week 24 among moderate to severe HS patients.
Eligibility Criteria
Inclusion Criteria: 1. Male or Female adult patients ≥18 years of age at the time of data collection. 2. Patient with a confirmed diagnosis of active moderate to severe HS. 3. Secukinumab naive patients (first dose to coincide within one month of the signature of the informed consent) as per locally approved label. 4. Patients can be using antibiotics or have undergone surgery as per routine clinical practice. 5. Patients agree to sign an informed consent form (ICF) to be able to complete the questionnaires. Exclusion Criteria: 1. Patients not fulfilling any of the above-mentioned inclusion criteria. 2. Patient's refusal to be included in the study or refusal to sign the ICF. 3. A history of off-label indication uses of biological treatment or JAK inhibitor.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06785779 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 99 Years, studying Hidradenitis Suppurativa (HS). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06785779 currently recruiting?
Yes, NCT06785779 is actively recruiting participants. Contact the research team at novartis.email@novartis.com for enrollment information.
Where is the NCT06785779 trial being conducted?
This trial is being conducted at Riyadh, Saudi Arabia, Jeddah, Saudi Arabia, Jeddah, Saudi Arabia, Riyadh, Saudi Arabia.
Who is sponsoring the NCT06785779 clinical trial?
NCT06785779 is sponsored by Novartis Pharmaceuticals. The trial plans to enroll 77 participants.